Community News
Dec. 21, 2013
Arnold & Porter, BayBio host panel talk on FDA approval process
Arnold & Porter LLP's San Francisco office hosted a panel discussion Monday aimed at providing an update on recent regulatory developments impacting the biotechnology and life sciences industries, particularly pharmaceutical developers. The discussion, titled "Breakthrough or More of the Same? New Pathways and Exclusivities in FDA Approval Processes," was held in conjunction with BayBio, a life sciences advocacy and consulting group, and brought together professionals from the legal, regulatory, biotechnology and financing worlds to discuss the latest trends in the Food and Drug Administration's approach to approving innovative new drugs. Congresswoman Jackie Speier served as one of the panelists, giving the audience a breakdown of recent congressional developments impacting the life sciences industry. BioMarin CEO Gail Maderis called Speier "a tremendous friend of life science innovation." — Dominic Fracassa
Arnold & Porter LLP's San Francisco office hosted a panel discussion Monday aimed at providing an update on recent regulatory developments impacting the biotechnology and life sciences industries, particularly pharmaceutical developers.
The discussion, titled "Breakthrough or More of the Same? New Pathways and Exclusivities in FDA Approval Processes," was held in conjunction with BayBio, a life sciences advocacy and consulting group, and brought together professional...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In